NCT02787317

Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,770 (estimated)
• Sponsor: Chinese PLA General Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Prolonging infusions may decrease myocardial damage associated with bivalirudin use during primary PCI. The investigators hypothesized that continuing the bivalirudin infusion commenced during the procedure at the PCI recommended dose for 4 hours would prevent myocardial damage.

Detailed description

Bivalirudin is widely used as an anticoagulant during percutaneous coronary intervention (PCI) for coronary heart disease. Prolonging infusions may decrease myocardial damage associated with bivalirudin use during primary PCI . However, whether prolonging infusions of bivalirudin could prevent ischemic complications is unknown. The investigators examined the effects of prolonged drug infusion after elective PCI. The investigators hypothesized that continuing the bivalirudin infusion commenced during the procedure at the PCI recommended dose for 4 hours would prevent myocardial damage.

Conditions

• Coronary Disease

Interventions

Type	Name	Description
DRUG	bivalirudin	Bivalirudin is an alternative to heparin in patients undergoing percutaneous coronary intervention.
DRUG	Heparin	Heparin is used in patients undergoing percutaneous coronary intervention.

Timeline

• Start date: 2016-05-01
• Primary completion: 2017-10-01
• Completion: 2018-11-01
• First posted: 2016-06-01
• Last updated: 2016-06-01

Locations

2 sites across 1 country: China